The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

A COMPARATIVE STUDY OF VARIOUS ATARACTIC DRUGS

Published Online:https://doi.org/10.1176/ajp.113.7.589

1. Clinical evaluations have been made upon 1,450 trials with chlorpromazine, a combination of Thorazine and reserpine, Frenquel, Pacatal, and Serpasil.

2. The patient material utilized for this study consisted of a very chronic, inpatient population of a state hospital with a very high percentage of schizophrenic reactions.

3. All 5 compounds tested appear to be of benefit in some respect, but not to the same degree.

4. Thorazine appears to be the most generally effective, and Frenquel the least.

5. All drugs appear most effective in the treatment of early cases and least effective in the very chronic.

6. High dosages of drugs do not appear to provide any benefit over and above the benefit derived from moderate dosage.

7. The incidence of side-effects is highest with Thorazine and Thorazine combined with reserpine and lowest with Frequel.

8. Combined Thorazine-reserpine therapy does not follow the prediction that the good effects of each drug would be potentiated and the ill effects merely additive. Thorazine-reserpine produces a prohibitively high incidence of serious untoward effects.

9. Patients who do not respond to one drug may respond to another. Patients who respond moderately to one drug may respond maximally to another.

10. No single diagnostic category seems to respond outstandingly to any one drug.

11. Hyperactivity, combativeness and tension respond best to ataraxics. The response of insight, affect, judgment, and realistic planning is disappointing.

12. Our results support the concept that ataractic drugs are of value in the treatment of psychiatric disorders.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.